Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A sympathomimetic with alpha-adrenergic action. It produces peripheral vasoconstriction and increased blood pressure without stimulating effects on the central nervous system.
Used as decongestant in topical nasal preparations at low concentration, in association with other drugs, in oral preparations to treat respiratory catarrh (Nice 2000, Kanfer 1993) and in eye drops at concentrations of up to 10% as a mydriatic. It is also used subcutaneously or intramuscularly in severe hypotensive states and in association with topical anesthetics.
Since the last update, we have not found published data on its excretion in breast milk.
The low dose of phenylephrine in nasal, ophthalmic and topical preparations makes its unlikely that it will transfer into breastmilk in significant amounts. It is prudent to press on the tear glands after adminitering eye drops in order to reduce absorption.
Its low oral bioavailability complicates its transfer to the infant’s plasma from ingested breastmilk, except in premature babies and the immediate neonatal period in which there may be increased intestinal permeability.
Nasal and ophthalmic use is authorized in children under one year of age.
Avoid excessive or prolonged oral use and use the minimum sufficient dose.
A similar molecule, pseudoephedrine, can cause a decrease in milk production (Aljazaf 2003).
See below the information of this related product: